Concentra 10-Q: Q3 Revenue Up 8.6% to $622.1M, EPS $0.52; New DOJ Probe Disclosed
CON has more than doubled off its 52-week low of $18.545.
Summary
Concentra's Q3 10-Q confirms 8.6% revenue growth to $622.1 million and EPS of $0.52 with leverage at 2.90x, and newly discloses that the DOJ opened a separate False Claims Act investigation into its physical therapy billing.
Key Events · Earnings and Guidance · CON
-
Q3 Revenue and EPS Growth Confirmed
Revenue rose 8.6% to $622.1 million from $572.8 million, and net income attributable to the Company rose 36.5% to $65.9 million, or $0.52 per diluted share versus $0.38.
-
Adjusted EBITDA Margin Expands
Adjusted EBITDA was $140.2 million, or 22.5% of revenue, versus $118.9 million and 20.8% a year earlier; nine-month Adjusted EBITDA reached $401.9 million.
-
New DOJ False Claims Investigation
The filing states that on September 9, 2026 the DOJ informed the Company it is the subject of a separate investigation under the False Claims Act regarding physical therapy billing; outcome and financial impact cannot currently be predicted.
-
Leverage at 2.90x, Ample Liquidity
The leverage ratio was 2.90x against a 6.50x covenant, with $85.8 million of cash and $430.3 million available under the revolver after $19.7 million of letters of credit and no revolver borrowings.
Analysis · CON · Industrial Applications And Services
The headline numbers were already out via this morning's 8-K, but the full 10-Q confirms the quality of the quarter: revenue of $622.1 million and EPS of $0.52 came with Adjusted EBITDA of $140.2 million (22.5% of revenue) and a leverage ratio down to 2.90x against a 6.50x covenant, leaving $430.3 million of revolver capacity and no revolver borrowings. The genuinely new item is legal: the filing states that on September 9, 2026 the DOJ told Concentra it is the subject of a separate False Claims Act investigation into physical therapy billing, on top of the previously disclosed California whistleblower suit and state insurance department subpoena. That is an unquantified but open-ended liability in the company's core revenue line, and it is the reason this filing matters beyond the earnings repeat.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CON was trading at $41.99 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $18.55 to $44.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.